Page last updated: 2024-08-25

clarithromycin and Escherichia coli Infections

clarithromycin has been researched along with Escherichia coli Infections in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (12.50)	18.2507
2000's	5 (62.50)	29.6817
2010's	1 (12.50)	24.3611
2020's	1 (12.50)	2.80

Authors

Authors	Studies
Castelletti, S; Cirioni, O; Ghiselli, R; Giacometti, A; Kamysz, E; Kamysz, W; Orlando, F; Riva, A; Rocchi, M; Saba, V; Scalise, G; Silvestri, C	1
Huang, E; Kaufmann, Y; Moon, SH	1
de Souza Carvalho-Wodarz, C; Dimer, F; Hartmann, R; Haupenthal, J; Lehr, CM	1
Bosnjak, B; Eraković Haber, V; Glojnarić, I; Hrvacić, B; Kramarić, MD; Pasalić, I; Situm, K; Tkalcević, VI	1
De Schepper, J; De Schutter, I; De Wachter, E; Malfroot, A; Vanbesien, J	1
Antonopoulou, A; Baziaka, F; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kousoulas, V; Koutoukas, P; Panagou, C; Perrea, D; Sabracos, L	1
Adamis, T; Baziaka, F; Giamarellos-Bourboulis, E; Giamarellou, H; Karayannacos, P; Koutoukas, P; Plachouras, D; Raftogiannis, M; Sabracos, L; Tsaganos, T	1
Müller, O	1

Trials

1 trial(s) available for clarithromycin and Escherichia coli Infections

Article	Year
Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. The Journal of antimicrobial chemotherapy, 1993, Volume: 31 Suppl E Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Azithromycin; Bacterial Infections; Child; Clarithromycin; Drug Administration Schedule; Erythromycin; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Otitis Media; Pharyngitis; Respiratory Tract Infections; Sinusitis; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes; Tonsillitis	1993

Article

Year

Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections.

The Journal of antimicrobial chemotherapy, 1993, Volume: 31 Suppl E

Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Azithromycin; Bacterial Infections; Child; Clarithromycin; Drug Administration Schedule; Erythromycin; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Otitis Media; Pharyngitis; Respiratory Tract Infections; Sinusitis; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes; Tonsillitis

1993

Other Studies

7 other study(ies) available for clarithromycin and Escherichia coli Infections

Article	Year
Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:12 Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Clarithromycin; Disease Models, Animal; DNA-Binding Proteins; Drug Therapy, Combination; Endotoxins; Escherichia coli; Escherichia coli Infections; Humans; Male; Peptides, Cyclic; Rats; Rats, Wistar; Sepsis; Treatment Outcome; Tumor Necrosis Factor-alpha	2008
Paenipeptin Analogues Potentiate Clarithromycin and Rifampin against Antimicrobial agents and chemotherapy, 2020, 03-24, Volume: 64, Issue:4 Topics: Animals; Bacterial Outer Membrane; Clarithromycin; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Mice; Polymyxins; Rifampin	2020
Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections. Pharmaceutical research, 2015, Volume: 32, Issue:12 Topics: Administration, Inhalation; Anti-Bacterial Agents; Cell Line; Clarithromycin; Dry Powder Inhalers; Escherichia coli; Escherichia coli Infections; Humans; Particle Size; Respiratory Tract Infections; Solubility; Staphylococcal Infections; Staphylococcus aureus	2015
The anti-inflammatory activity of clarithromycin inhibits TNFalpha production and prolongs survival following lipopolysaccharide administration in mice. International journal of antimicrobial agents, 2008, Volume: 32, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Clarithromycin; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Humans; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Shock, Septic; Treatment Outcome; Tumor Necrosis Factor-alpha	2008
Inhaled budesonide induced Cushing's syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2003, Volume: 2, Issue:2 Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antifungal Agents; Aspergillosis, Allergic Bronchopulmonary; Aspergillus fumigatus; Bronchodilator Agents; Budesonide; Clarithromycin; Cushing Syndrome; Cystic Fibrosis; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Synergism; Drug Therapy, Combination; Escherichia coli Infections; Fatal Outcome; Female; Humans; Iatrogenic Disease; Infant, Newborn; Itraconazole; Lung Diseases; Male; Mycobacterium Infections, Nontuberculous	2003
Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli. International journal of antimicrobial agents, 2005, Volume: 25, Issue:2 Topics: Acute Disease; Amikacin; Animals; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Female; Humans; Inflammation; Lipopolysaccharides; Malondialdehyde; Pyelonephritis; Rabbits; Sepsis; Treatment Outcome; Tumor Necrosis Factor-alpha	2005
Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. Scandinavian journal of infectious diseases, 2005, Volume: 37, Issue:1 Topics: Acute Disease; Amikacin; Animals; Anti-Bacterial Agents; Caspase 3; Caspases; Clarithromycin; Colony Count, Microbial; Escherichia coli; Escherichia coli Infections; Immunologic Factors; Male; Malondialdehyde; Pulmonary Edema; Pyelonephritis; Rabbits; Sepsis; Tumor Necrosis Factor-alpha	2005